Answers are grounded in this paper and cite their sources.
Mesenchymal-epithelial transition (MET) receptor tyrosine kinase is overexpressed, amplified, or mutated in 1– 20% of NSCLC. MET dysregulation is associated with a poor prognosis. Recently, development of targeted therapies against MET exon 14 mutations has demonstrated efficacy and tolerability in early trials. Here we focus on tepotinib and capmatinib in regards to molecular characteristics, early preclinical and clinical data, and the emerging role in future studies and clinical practice.
No takes yet. Share an insight, caveat, or question.
Brazel et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: